This construct was specifically designed to target the prostate-specific membrane antigen (PSMA), an exopeptidase highly expressed on the apical plasma membrane of prostate cancer (PC) cells but also found in high percentage in endothelial cells from many different malignancies, including bladder, gastric, and colorectal, as well as hepatocellular, renal, breast, and ovarian cancer [179]. Here, FOLH1 is linked to prostate carcinoma.